Is LivaNova PLC Undervalued: UK Stock Analysis and Market Performance

LivaNova PLC (LIVN) is one of the best undervalued UK stocks to buy right now. The UK and European markets saw excellent returns in Q1 2025 due to factors like the approval of a 500 billion Euro infrastructure fund, lifting of restrictions on defense spending in Germany, and stimulus from the Chinese government. The UK banking sector grew earnings by 30% YoY and used excess cash to buy back stocks and increase dividends. Tariffs may impact the UK's growth in the longer run, but LIVN remains a promising investment opportunity.

LivaNova PLC (LIVN) has emerged as one of the best undervalued UK stocks to buy, particularly in the context of the robust performance seen in the UK and European markets during Q1 2025. Several factors contributed to this positive trend, including the approval of a 500 billion Euro infrastructure fund, the lifting of restrictions on defense spending in Germany, and stimulus from the Chinese government. Additionally, the UK banking sector reported a 30% year-over-year (YoY) growth in earnings, which was used to buy back stocks and increase dividends [1].

Despite potential long-term impacts from tariffs, LivaNova remains a promising investment opportunity. The company is a key player in the neuromodulation devices market, which is experiencing significant growth. The market is driven by advancements in neurological therapies and the rising prevalence of neurological disorders. LivaNova's neuromodulation devices are used to treat a range of conditions, including chronic pain, Parkinson’s disease, and epilepsy, among others [2].

In March 2025, Sooma Medical received FDA Investigational Device Exemption (IDE) for its transcranial direct current stimulation (tDCS) device, allowing the company to begin a pivotal study of the device for treating depression. This approval underscores the growing demand for innovative neuromodulation therapies [3].

Moreover, in February 2025, Medtronic received FDA approval for its BrainSense™ Adaptive deep brain stimulation (aDBS) for Parkinson's disease, marking a significant advancement in neuromodulation therapy. Such innovations are likely to drive further growth in the neuromodulation devices market [4].

The neuromodulation devices market is expected to grow at a compound annual growth rate (CAGR) of 8.95% from 2025 to 2032, reaching a valuation of USD 9.56 billion by 2032. North America is anticipated to dominate the market during this period, driven by the rising prevalence of neurological disorders and increasing product development by key industry players [5].

LivaNova's position in this market, combined with the broader economic trends favoring the UK and European markets, makes it an attractive investment opportunity. While tariffs pose a potential risk, the company's strong market position and the overall growth trajectory of the neuromodulation devices market suggest that LivaNova is well-positioned for future success.

References:
[1] https://www.barchart.com/story/news/32005736/neuromodulation-devices-market-to-grow-at-a-cagr-of-895-by-2032-fueled-by-advancements-in-neurological-therapies-and-rising-prevalence-of-neurological-disorders-delveinsight
[2] https://www.barchart.com/story/news/32005736/neuromodulation-devices-market-to-grow-at-a-cagr-of-895-by-2032-fueled-by-advancements-in-neurological-therapies-and-rising-prevalence-of-neurological-disorders-delveinsight
[3] https://www.barchart.com/story/news/32005736/neuromodulation-devices-market-to-grow-at-a-cagr-of-895-by-2032-fueled-by-advancements-in-neurological-therapies-and-rising-prevalence-of-neurological-disorders-delveinsight
[4] https://www.barchart.com/story/news/32005736/neuromodulation-devices-market-to-grow-at-a-cagr-of-895-by-2032-fueled-by-advancements-in-neurological-therapies-and-rising-prevalence-of-neurological-disorders-delveinsight
[5] https://www.barchart.com/story/news/32005736/neuromodulation-devices-market-to-grow-at-a-cagr-of-895-by-2032-fueled-by-advancements-in-neurological-therapies-and-rising-prevalence-of-neurological-disorders-delveinsight

Ask Aime: How can I invest in LivaNova PLC (LIVN) right now?

View Source